2 citations
,
May 2019 in “BioTechniques” Industry 4.0 is transforming labs with new tools, making research more efficient and environmentally friendly.
149 citations
,
August 2022 in “Biochemistry (Moscow)” CRISPR-Cas9 allows precise DNA editing but raises ethical concerns about modifying human embryos.
The research developed new fortilin protein constructs for potential heart disease treatments.
June 2024 in “International Journal of Nanomedicine” CRISPR/Cas9 has improved precision and control but still faces clinical challenges.
9 citations
,
March 2022 in “Journal of Chemical Information and Modeling” New inhibitors may reduce gut toxicity from cancer drugs.
12 citations
,
June 2021 in “Scientific Reports” Curcumin may help reverse aging by targeting specific genes.
December 2024 in “Turkish Journal of Forensic Medicine” Next-Generation Sequencing improves forensic analysis by providing detailed genetic information quickly.
March 2026 in “Zenodo (CERN European Organization for Nuclear Research)” The N-K GM Series offers highly selective, eco-friendly medicines targeting harmful microbes, free for personal use.
11 citations
,
May 2023 in “Journal of Cancer Research and Clinical Oncology” CRISPR/Cas systems show promise for cancer treatment by targeting miRNAs, but delivery and specificity challenges remain.
April 2011 in “ChemInform” A new compound may effectively inhibit the enzyme linked to BPH and hair loss.
8 citations
,
May 2025 in “Biomolecules” Forensic genetics can now predict physical traits and lifestyle habits, with future advancements expected from new technologies.
2 citations
,
December 2023 in “Biointerface Research in Applied Chemistry” RNA-Seq is now the standard for detailed gene expression analysis.
10 citations
,
December 2023 in “International Journal of Nanomedicine” Cell membrane-coated nanoparticles could improve gene therapy by enhancing delivery and targeting of nucleic acids.
32 citations
,
April 2024 in “Nature Biotechnology”
Understanding genetics is crucial for treating heart and skin diseases.
February 2025 in “Biointerface Research in Applied Chemistry” Repurposing existing drugs can quickly and cheaply find new treatments for diseases.
9 citations
,
April 2019 in “Food Chemistry” Created large amounts of grape seed compounds using a new method.
March 2024 in “Organic letters” A new method efficiently modifies alkenes to create useful medicinal compounds.
March 2026 in “Zenodo (CERN European Organization for Nuclear Research)” The N-K GM Series offers highly selective, eco-friendly antimicrobials free for everyone.
October 2023 in “Biomedical science and engineering” Innovative methods are reducing animal testing and improving biomedical research.
January 2015 in “Journals & Books Hosting (International Knowledge Sharing Platform)” Compound 1 showed promising anticancer activity.
9 citations
,
January 2025 in “Droplet” Precise cell manipulation technologies are advancing but still face challenges in improving accuracy for medical use.
7 citations
,
April 2024 in “Life Medicine” Standardizing and engineering organoids can improve their use in medicine and drug testing.
November 2020 in “The Royal Society of Chemistry eBooks” Peptides are being used to create biomaterials that can help diagnose and treat diseases.
September 2025 in “Experimental & Molecular Medicine” Small molecules KY19382 and KY19334 may help treat skin cancer by reducing CDK1 levels and blocking harmful cell signals.
26 citations
,
January 2014 in “ALTEX” Pesticides can cause reproductive and adrenal health issues.
3 citations
,
August 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” The DNN-DTIs method accurately predicts drug-target interactions and is useful for drug repositioning.
94 citations
,
July 2020 in “European Journal of Human Genetics” The guidelines ensure accurate genetic testing and reporting for 21-hydroxylase deficiency.
Machine learning improves DNA predictions for eye and hair color, but challenges remain for skin tone and facial features.
1 citations
,
May 2022 in “The FASEB journal” The document concludes that biotin, folate, and RGD peptides are promising for targeting cancer cells with prodrugs, but the conjugates are not yet tested for use.